Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.
BACKGROUND
Iron deficiency is a common cause of anaemia in non-dialysis chronic kidney disease (ND-CKD). Controversies exist about the optimal route of administration for iron therapy. Liposomal iron, a new generation oral iron with high gastrointestinal absorption and bioavailability and a low incidence of side effects, seems to be a promising new strategy of iron replacement. Therefore, we conducted a study to determine whether liposomal iron, compared with intravenous (IV) iron, improves anaemia in ND-CKD patients.


METHODS
In this randomized, open-label trial, 99 patients with CKD (stage 3-5, not on dialysis) and iron deficiency anaemia [haemoglobin (Hb) ≤12 g/dL, ferritin ≤100 ng/mL, transferrin saturation ≤25%] were assigned (2:1) to receive oral liposomal iron (30 mg/day, Group OS) or a total dose of 1000 mg of IV iron gluconate (125 mg infused weekly) (Group IV) for 3 months. The patients were followed-up for the treatment period and 1 month after drug withdrawal. The primary end point was to evaluate the effects of the two treatments on Hb levels; the iron status, compliance and adverse effects were also evaluated.


RESULTS
The short-term therapy with IV iron produced a more rapid Hb increase compared with liposomal iron, although the final increase in Hb was similar with either treatment; the difference between the groups was statistically significant at the first month and such difference disappeared at the end of treatment. After iron withdrawal, Hb concentrations remained stable in Group IV, while recovered to baseline in the OS group. The replenishment of iron stores was greater in the IV group. The incidence of adverse event was significantly lower in the oral group (P < 0.001), and the adherence was similar in the two groups.


CONCLUSIONS
Our study shows that oral liposomal iron is a safe and efficacious alternative to IV iron gluconate to correct anaemia in ND-CKD patients, although its effects on repletion of iron stores and on stability of Hb after drug discontinuation are lower.
Department of Public Health, University Federico II of Naples, Naples, Italy.
Antonio
A
Pisani
Department of Public Health, University Federico II of Naples, Naples, Italy.
Eleonora
E
Riccio
Department of Public Health, University Federico II of Naples, Naples, Italy.
Massimo
M
Sabbatini
Department of Nephrology, Magna Graecia University, Catanzaro, Italy.
Michele
M
Andreucci
Department of Biochemistry and Medical Technology, University Federico II of Naples, Naples, Italy.
Antonio
A
Del Rio
Department of Public Health, University Federico II of Naples, Naples, Italy.
Bianca
B
Visciano
D061605:Administration, Intravenous; D000284:Administration, Oral; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005942:Gluconates / Q000008:administration & dosage*; D006801:Humans; D058085:Iron Compounds / Q000008:administration & dosage*; D008081:Liposomes / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D051436:Renal Insufficiency, Chronic / Q000150:complications*
D005942:Gluconates; D058085:Iron Compounds; D008081:Liposomes; C030691:gluconic acid
anaemia; erythropoiesis; inflammation; iron-deficiency